Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

121. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. Full Text available with Trip Pro

Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children. Guidelines and clinical practice for the prevention of complications associated with central venous catheters (CVC) around the world vary greatly. Most institutions recommend the use of heparin to prevent occlusion, however there is debate regarding the need for heparin and evidence to suggest 0.9% sodium chloride (normal saline) may (...) be as effective. The use of heparin is not without risk, may be unnecessary and is also associated with increased cost.To assess the clinical effects (benefits and harms) of intermittent flushing of heparin versus normal saline to prevent occlusion in long term central venous catheters in infants and children.The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched April 2015) and the Cochrane Register of Studies (Issue 3, 2015). We also searched the reference lists

2015 Cochrane

122. Heparin-Induced Thrombocytopenia. Full Text available with Trip Pro

Heparin-Induced Thrombocytopenia. 26535527 2015 11 06 2018 12 02 1533-4406 373 19 2015 11 05 The New England journal of medicine N. Engl. J. Med. Heparin-Induced Thrombocytopenia. 1883 10.1056/NEJMc1510993 Hoover Jon J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antithrombins 0 Pipecolic Acids 9005-49-6 Heparin AIM IM N Engl J Med. 2015 Jul 16;373(3):252-61 26176382 N Engl J Med. 2015 Nov 5;373(19):1883-4 26535525 Antithrombins therapeutic use Female Heparin adverse

2015 NEJM

123. Heparin-Induced Thrombocytopenia. Full Text available with Trip Pro

Heparin-Induced Thrombocytopenia. 26535525 2015 11 06 2018 12 02 1533-4406 373 19 2015 11 05 The New England journal of medicine N. Engl. J. Med. Heparin-Induced Thrombocytopenia. 1883-4 10.1056/NEJMc1510993 Greinacher Andreas A eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antithrombins 0 Pipecolic Acids 9005-49-6 Heparin AIM IM N Engl J Med. 2015 Jul 16;373(3):252-61 26176382 N Engl J Med. 2015 Nov 5;373(19):1882-3 26535526 N Engl J Med. 2015 Nov 5;373(19):1883 26535527 (...) Antithrombins therapeutic use Female Heparin adverse effects Humans Pipecolic Acids therapeutic use Thrombocytopenia chemically induced 2015 11 5 6 0 2015 11 5 6 0 2015 11 7 6 0 ppublish 26535525 10.1056/NEJMc1510993 10.1056/NEJMc1510993#SA3

2015 NEJM

124. Heparin-Induced Thrombocytopenia. Full Text available with Trip Pro

Heparin-Induced Thrombocytopenia. 26535526 2015 11 06 2018 12 02 1533-4406 373 19 2015 11 05 The New England journal of medicine N. Engl. J. Med. Heparin-Induced Thrombocytopenia. 1882-3 10.1056/NEJMc1510993 Klarenbeek Naomi B NB Eikenboom Jeroen C J JC eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antithrombins 0 Pipecolic Acids 9005-49-6 Heparin AIM IM N Engl J Med. 2015 Jul 16;373(3):252-61 26176382 N Engl J Med. 2015 Nov 5;373(19):1883-4 26535525 Antithrombins (...) therapeutic use Female Heparin adverse effects Humans Pipecolic Acids therapeutic use Thrombocytopenia chemically induced 2015 11 5 6 0 2015 11 5 6 0 2015 11 7 6 0 ppublish 26535526 10.1056/NEJMc1510993 10.1056/NEJMc1510993#SA1

2015 NEJM

125. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis

2015 NIHR HTA programme

126. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. Full Text available with Trip Pro

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome.We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to receive either bivalirudin or unfractionated heparin. Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive (...) a post-PCI bivalirudin infusion. Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event). The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization, definite stent

2015 NEJM Controlled trial quality: predicted high

127. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. (Abstract)

Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. A daily injection of low-molecular-weight heparin (LMWH) is often prescribed to women with unexplained recurrent pregnancy loss (RPL), although evidence suggesting a benefit is questionable.To determine whether LMWH increases ongoing pregnancy and live-birth rates in women with unexplained RPL.Controlled, multicenter trial with randomization using

2015 Annals of Internal Medicine Controlled trial quality: predicted high

128. Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. (Abstract)

Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes?When used for perioperative thromboprophylaxis (...) , there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.

2015 JAMA

129. Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. Full Text available with Trip Pro

Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during (...) primary PCI.Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes).The primary end point

2015 JAMA Controlled trial quality: predicted high

130. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system Full Text available with Trip Pro

Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system To characterize heparin-induced thrombocytopenia (HIT) at a single pediatric center including the prevalence and the accuracy of the 4Ts scoring system as a predictor of HIT.In this retrospective cohort study, we identified 155 consecutive patients <21 years old with sufficient data for 4Ts scoring. The 4Ts scoring system is a validated pretest tool in adults that predicts (...) the likelihood of HIT using clinical features. Hospital-wide exposure to unfractionated and low molecular weight heparin was determined by querying the hospital pharmacy database.The majority of patients with suspected HIT (61.2%) were on surgical services. Prediction of HIT risk using initial 4Ts scoring found 3 (2%) had high risk 4Ts scores, 114 (73%) had intermediate risk 4Ts scores, and the remaining 38 (25%) had low risk 4Ts scores. HIT was confirmed in 0/38 patients with low risk 4Ts scores, 2/114

2015 EvidenceUpdates

131. Unfractionated Heparin and Low-Molecular-Weight Heparin

Unfractionated Heparin and Low-Molecular-Weight Heparin © 2013 Thrombosis Canada. Page 1 of 5 UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. ABBREVIATIONS: ALT alanine aminotransferase aPTT activated partial thromboplastin time AST aspartate aminotransferase AT antithrombin CBC complete blood count HIT heparin (...) -induced thrombocytopenia INR international normalized ratio IV intravenous LMWH low-molecular-weight heparin MI myocardial infarction PT prothrombin time TNK tenecteplase tPA tissue plasminogen activator UFH unfractionated heparin U units VTE venous thromboembolism MECHANISM OF ACTION: Unfractionated heparin (UFH) acts as an anticoagulant by forming a complex with antithrombin (AT) catalysing the inhibition of several activated blood coagulation factors: thrombin (factor IIa), factor IXa, Xa, XIa

2015 Thrombosis Interest Group of Canada

132. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. Full Text available with Trip Pro

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting

2015 JAMA

133. Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU

Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU "Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated " by Phoebe Robinson < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Acute lung injury (ALI) is a serious clinical concern (...) brought on by inflammatory triggers and is characterized by rapid onset of respiratory distress in the setting of inflammatory insult. Fibrin deposition from the inflammation leads to poor ventilation and perfusion. There is no current treatment for ALI other than supportive measures. Heparin is an anticoagulant that prevents fibrin deposition. Previous animal and ALI model studies have demonstrated improvement in lung function markers with nebulized heparin. This review looks at the effects

2015 Pacific University EBM Capstone Project

134. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis

The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2015 PROSPERO

135. The efficacy of heparin-grafted membrane for dialysis without systemic anticoagulation in hemodialysis patients at risk of bleeding

The efficacy of heparin-grafted membrane for dialysis without systemic anticoagulation in hemodialysis patients at risk of bleeding Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

136. Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children [Cochrane Protocol]

Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in infants and children [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2015 PROSPERO

137. Heparin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol]

Heparin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2015 PROSPERO

138. Heparin and related substances for treating diabetic foot ulcers [Cochrane Protocol]

Heparin and related substances for treating diabetic foot ulcers [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

139. Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair [Cochrane Protocol]

Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated

2015 PROSPERO

140. Intravenous heparin during ruptured abdominal aortic aneurysmal repair [Cochrane Protocol]

Intravenous heparin during ruptured abdominal aortic aneurysmal repair [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2015 PROSPERO